← BioNTech overview

BioNTech vs Euro/US Dollar FX Spot Rate: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BioNTech SE (22UA.XETRA)

Q3 2026
▼2▲1

BioNTech's cancer pipeline advances but COVID collapse and trial setback weigh

  • Cancer pipeline progress BioNTech's cancer pipeline gained traction: gotistobart showed strong Phase 3 lung cancer survival data, pumitamig advanced in kidney cancer, and Moderna/Merck's mRNA cancer vaccine success lifted sector sentiment.

    This is a key positive driver for the stock, showing pipeline potential.

  • COVID revenue collapse and guidance cut COVID revenue continues collapsing, forcing restructuring and a 2026 guidance cut to €1.6–1.9 billion, which pressures the company's financial outlook.

    This is a major negative factor affecting revenue and investor confidence.

  • Colorectal cancer trial halted BioNTech's own mRNA colorectal cancer trial was halted for futility and a survival imbalance, cutting shares and raising concerns about its pipeline.

    This is a significant setback that directly impacted the stock price.

  • Legal risks and leadership change Patent lawsuits from Arbutus/Roivant and Monsanto add legal risk, while a new CEO brings execution uncertainty and BMO downgraded the stock.

    These factors create uncertainty and negative sentiment, offsetting some positives.

September 2026
▲2▼2

Lung cancer win lifts BioNTech, but patent suit and downgrade weigh

  • Gotistobart nearly doubles lung cancer survival BioNTech and OncoC4 reported that gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial. This is the first strong sign that BioNTech's cancer pipeline can work, which supports the shares because investors have doubted the company's move beyond COVID vaccines.

    This is the period's biggest new positive and directly addresses doubts about BioNTech's cancer strategy.

  • Monsanto mRNA patent lawsuit moves forward A Delaware judge rejected BioNTech's bid to dismiss Monsanto's patent lawsuit over mRNA technology used in COVID-19 vaccines. The case can now proceed, creating legal uncertainty and potential future costs or royalties, which weighs on the shares.

    This is a new legal risk that could affect BioNTech's finances and is not in earlier reports.

  • BMO downgrade and price target cut BMO downgraded BioNTech to market perform and cut its price target to $105 from $128, citing the failed colorectal cancer trial and lower revenue guidance. Analyst downgrades can push the shares down because they signal weaker confidence in future earnings.

    This is a new analyst action that directly affects investor sentiment and the stock's perceived value.

  • Health Canada approves XFG-adapted COMIRNATY Health Canada approved BioNTech and Pfizer's XFG-adapted COVID-19 vaccine for people aged 6 months and older. This secures regulated seasonal revenue from Canada, helping offset weaker overall COVID demand and supporting the balance sheet.

    This is a new regulatory approval that adds a revenue stream and is not in earlier reports.

Latest
▲2▼2

Lung cancer win lifts BioNTech, but patent suit and downgrade weigh

  • Gotistobart nearly doubles lung cancer survival BioNTech and OncoC4 reported that gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial. This is the first strong sign that BioNTech's cancer pipeline can work, which supports the shares because investors have doubted the company's move beyond COVID vaccines.

    This is the period's biggest new positive and directly addresses doubts about BioNTech's cancer strategy.

  • Monsanto mRNA patent lawsuit moves forward A Delaware judge rejected BioNTech's bid to dismiss Monsanto's patent lawsuit over mRNA technology used in COVID-19 vaccines. The case can now proceed, creating legal uncertainty and potential future costs or royalties, which weighs on the shares.

    This is a new legal risk that could affect BioNTech's finances and is not in earlier reports.

  • BMO downgrade and price target cut BMO downgraded BioNTech to market perform and cut its price target to $105 from $128, citing the failed colorectal cancer trial and lower revenue guidance. Analyst downgrades can push the shares down because they signal weaker confidence in future earnings.

    This is a new analyst action that directly affects investor sentiment and the stock's perceived value.

  • Health Canada approves XFG-adapted COMIRNATY Health Canada approved BioNTech and Pfizer's XFG-adapted COVID-19 vaccine for people aged 6 months and older. This secures regulated seasonal revenue from Canada, helping offset weaker overall COVID demand and supporting the balance sheet.

    This is a new regulatory approval that adds a revenue stream and is not in earlier reports.

August 2026
▼2▲1

Cancer vaccine hopes clash with trial failure and weak guidance

  • Sector optimism from Moderna/Merck mRNA cancer vaccine success Moderna and Merck's Phase 3 mRNA cancer vaccine success lifted BioNTech shares about 22%, as investors bet the whole mRNA cancer field could win. BioNTech also reported promising first-in-class lung cancer data and won EU and FDA approvals for an updated COVID vaccine.

    This sector-wide rally and positive pipeline news were a major force pushing BioNTech shares up during the month.

  • Own mRNA colorectal cancer trial halted for futility and survival imbalance BioNTech's own Phase 2 mRNA colorectal cancer vaccine trial was stopped for futility and later for a survival imbalance, cutting shares 10% and then 7.5%. This directly undercut the optimism from the sector news and reminded investors that not all mRNA cancer bets will work.

    This was a major negative event that dragged BioNTech's stock down and highlighted pipeline risk.

  • 2026 revenue guidance cut on weak COVID demand BioNTech reduced its 2026 revenue guidance to €1.6–1.9 billion because COVID vaccine demand remains weak. This confirmed the company's main revenue source is still shrinking, adding pressure on the stock and raising doubts about near-term earnings.

    The guidance cut is a key negative driver that directly affects investor expectations for BioNTech's financial performance.

  • New CEO and strong cash cushion, but execution uncertainty BioNTech named a new CEO, creating strategic uncertainty, though it still holds €16.6 billion in cash. Upcoming ESMO data and a head-and-neck cancer interim analysis are key catalysts, but pipeline risk, rising competition, and execution challenges remain.

    This captures the mixed balance of a strong cash position and upcoming catalysts against leadership change and execution risks.

▼2▲1

BioNTech cuts guidance, replaces CEO, and halts a cancer vaccine trial

  • 2026 revenue guidance cut on weak COVID demand BioNTech lowered its 2026 revenue forecast to €1.6–1.9 billion from €2.0–2.3 billion, mainly because COVID-19 vaccine demand is weaker than expected. Less money coming in makes the shares less attractive, even though the company still holds €16.6 billion in cash.

    A direct cut to expected sales is a core reason the stock is under pressure.

  • New CEO named as company shifts focus Guido Oelkers will become CEO by February 1, replacing the current leadership. A new boss can bring fresh direction, but it also creates uncertainty about strategy and execution while BioNTech tries to move beyond COVID vaccines into cancer treatments.

    Leadership change is a major event that affects investor confidence and future strategy.

  • Colorectal cancer vaccine trial stopped for survival imbalance BioNTech ended a mid-stage trial of its personalized mRNA cancer vaccine in colorectal cancer after a monitoring committee saw a survival imbalance between groups. This raises doubts about the mRNA cancer strategy and sent shares down 7.5%, reminding investors that most cancer vaccine attempts still fail.

    The trial halt is a direct setback to the pipeline that investors hoped would drive future growth.

  • EU and FDA approvals for updated COVID vaccine European and U.S. regulators authorized BioNTech and Pfizer's XFG-adapted COVID-19 vaccine for the fall season. This allows sales in 27 EU countries plus the U.S., providing some near-term revenue even as overall COVID demand softens.

    Regulatory approvals secure near-term sales and partially offset the weak demand outlook.

▲2▼1

mRNA cancer hopes lift BioNTech, then its own trial fails

  • Rival's mRNA cancer win lifts whole sector Moderna and Merck's Phase 3 mRNA cancer vaccine success in melanoma sent biotech stocks to post-pandemic highs and lifted BioNTech about 22%. Investors read it as proof that mRNA cancer treatments can work, which supports BioNTech's own pipeline value.

    This sector-wide read-across was the main force pushing BioNTech shares up during the period.

  • New lung cancer data shows pipeline progress BioNTech presented first-in-class lung cancer data combining pumitamig with a B7H3 antibody-drug conjugate at a major conference. It signals real progress beyond COVID vaccines, but the company is still unprofitable and depends on late-stage trials succeeding.

    It is a company-specific pipeline update that supports the growth story behind the stock.

  • Own mRNA cancer vaccine trial fails BioNTech stopped a Phase 2 mRNA cancer vaccine trial for colorectal cancer due to futility, and shares fell 10%. The failure contrasts with Moderna's success and reminds investors that most cancer vaccine attempts still fail, so pipeline risk remains high.

    This is the period's biggest company-specific negative event and directly answers why the stock moved.

  • Competition and cash define the outlook Moderna's win increases competition in personalized cancer vaccines, but BioNTech still holds €16.6 billion in cash and securities. Upcoming data at ESMO in October and a head and neck cancer interim analysis are the next catalysts that could restore or further dent confidence.

    It gives the balanced counterweight: competitive pressure versus financial strength and upcoming catalysts.

July 2026
▲2▼2

BioNTech's cancer push grows, but COVID decline and patent suits weigh

  • Cancer pipeline advances BioNTech's mRNA cancer vaccines and personalized immunotherapies are gaining recognition, and its jointly developed drug pumitamig is being tested in a new kidney cancer trial. These moves support future revenue potential beyond COVID, which could lift the stock as investors bet on long-term growth.

    Shows new progress in BioNTech's key growth area, oncology, which is central to its future value.

  • Takeover interest and strong cash BioNTech is seen as a potential acquisition target due to its €16.8 billion in cash and a pipeline with over 25 mid- to late-stage trials. A buyout could offer a premium to the current share price, though any deal is speculative and not guaranteed.

    Highlights a possible catalyst that could significantly boost the stock if a takeover materializes.

  • COVID revenue collapse forces restructuring BioNTech is exiting German manufacturing sites and selling its peptide unit as COVID vaccine demand plunges, with revenue falling from $21.6 billion in 2021 to $3.4 billion in 2025. This reflects the loss of its main revenue source and adds uncertainty, pressuring the stock.

    Directly explains a major negative force: the sharp decline in BioNTech's core COVID business and its cost-cutting response.

  • New patent lawsuits over COVID vaccine Arbutus and Roivant have filed international patent suits against Pfizer and BioNTech over lipid nanoparticle technology used in Comirnaty, seeking injunctions and damages. This adds legal risk and potential financial liability, which could weigh on the stock.

    Represents a fresh legal threat that could result in significant costs or restrictions on a key product.

▲2▼2

BioNTech's cancer push grows, but COVID decline and patent suits weigh

  • Cancer pipeline advances BioNTech's mRNA cancer vaccines and personalized immunotherapies are gaining recognition, and its jointly developed drug pumitamig is being tested in a new kidney cancer trial. These moves support future revenue potential beyond COVID, which could lift the stock as investors bet on long-term growth.

    Shows new progress in BioNTech's key growth area, oncology, which is central to its future value.

  • Takeover interest and strong cash BioNTech is seen as a potential acquisition target due to its €16.8 billion in cash and a pipeline with over 25 mid- to late-stage trials. A buyout could offer a premium to the current share price, though any deal is speculative and not guaranteed.

    Highlights a possible catalyst that could significantly boost the stock if a takeover materializes.

  • COVID revenue collapse forces restructuring BioNTech is exiting German manufacturing sites and selling its peptide unit as COVID vaccine demand plunges, with revenue falling from $21.6 billion in 2021 to $3.4 billion in 2025. This reflects the loss of its main revenue source and adds uncertainty, pressuring the stock.

    Directly explains a major negative force: the sharp decline in BioNTech's core COVID business and its cost-cutting response.

  • New patent lawsuits over COVID vaccine Arbutus and Roivant have filed international patent suits against Pfizer and BioNTech over lipid nanoparticle technology used in Comirnaty, seeking injunctions and damages. This adds legal risk and potential financial liability, which could weigh on the stock.

    Represents a fresh legal threat that could result in significant costs or restrictions on a key product.

Euro/US Dollar FX Spot Rate (EURUSD.FOREX)

Q3 2026
▲2▼1

Euro swings from two-month high to 17-month low as Fed hikes and French debt fears dominate

  • Euro hits two-month high on weak US jobs and split Fed The euro climbed to a two-month high near 1.166 as weak US jobs data and a divided Federal Reserve weakened the dollar, while solid eurozone activity and expected ECB rate hikes supported the currency.

    This explains the euro's peak during the period, driven by US dollar weakness and eurozone strength.

  • Euro plunges to 17-month low on Fed hikes and French debt The euro fell to a 17-month low as Federal Reserve rate hikes, 5.2% Treasury yields, French debt concerns, German far-right election gains, and energy shocks weighed heavily on the currency.

    This captures the main downward driver that pushed the euro to its lowest level in 17 months.

  • ECB rate hikes to 2.50% and resilient PMI offer partial support The European Central Bank raised rates to 2.50% and eurozone business activity remained resilient, providing only partial support to the euro amid broader negative forces.

    This shows the counterweight that limited the euro's decline, balancing the negative drivers.

September 2026
▼3▲1

Euro Falls to 17-Month Low as Dollar Strength and Eurozone Risks Dominate

  • Dollar Strength on Fed Hikes and High Yields The Fed raised rates to 3.75–4.00% and US 10-year yields topped 5.2%, pulling global money into dollar assets. This made the dollar more attractive and pushed the euro down.

    This is a key new force that drove EURUSD lower during the period.

  • Eurozone Political and Fiscal Risks Weigh on Euro France's debt neared 120% of GDP with widening bond spreads, and far-right gains in German elections raised concerns. These risks made investors wary of holding euros.

    New political developments added downward pressure on the euro.

  • Energy Shocks Hurt Europe's Growth Outlook Brent crude rose above $100 and natural gas above €80/MWh, raising costs for European businesses and consumers. This weakened the eurozone economy and weighed on the euro.

    Energy price spikes are a new negative factor for the euro.

  • ECB Hikes and Resilient Economy Support Euro Eurozone inflation hit 3.8%, prompting the ECB to raise rates to 2.50% and signal more tightening. The economy held up with PMI at 53.1, attracting some foreign capital.

    This positive force partially offset the euro's decline and is new this period.

Latest
▼3▲1

Dollar surges on Fed hike bets and French debt fears; eurozone inflation offers partial support

  • Fed rate-hike bets and surging US yields lift the dollar Rising oil prices and strong US data pushed markets to price a 70% chance of another Fed hike in October, sending 10-year Treasury yields above 5.2%. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down to a 17-month low near 1.123.

    This is the main new force driving the dollar higher and the euro lower this period.

  • French debt and political worries trigger euro selling Investors dumped French bonds, stocks and the euro as public debt nears 120% of GDP and the budget faces a divided parliament. The French-German bond yield gap widened past 140 basis points, and Bank of America estimates the euro falls 0.4% for every 10bp of spread widening, dragging EURUSD down.

    French fiscal stress is a new, major driver of euro weakness this period.

  • Energy shock and European political risk keep euro near lows The Iran war disrupted LNG shipments through the Strait of Hormuz, pushing European gas above €80/MWh, while far-right gains in German state elections weakened Chancellor Merz. High energy hurts Europe's growth and political uncertainty scares investors, both weighing on the euro and pushing EURUSD down.

    Energy and political risk are key new pressures on the euro this period.

  • Eurozone inflation beats forecasts, keeping ECB hike hopes alive September eurozone inflation rose to 3.8%, above the 3.6% forecast, with core inflation up to 2.5%. This keeps pressure on the ECB to raise rates further, which attracts global money into the euro and supports EURUSD, though markets still see only a one-in-three chance of an October hike.

    This is the main new counterweight supporting the euro against the strong dollar.

▲2▼2

Eurozone data and ECB signals support euro, but US yields and politics weigh

  • Eurozone economy unexpectedly strong, supports euro The eurozone's business activity index jumped to 53.1 in September, the highest in over three years, beating expectations. A stronger economy makes the euro more attractive and supports further ECB rate hikes, pushing EURUSD up.

    This is new data showing eurozone resilience, which strengthens the euro.

  • ECB officials hint at more rate hikes to fight inflation ECB's Nagel said rates may need to become restrictive, and Makhlouf said the ECB would act if energy prices spill over. BofA expects a December hike. Higher expected euro rates attract global money, pushing EURUSD up.

    New hawkish comments from ECB officials and BofA's forecast reinforce expectations of higher euro rates.

  • US bond yields surge and Fed officials back more hikes The 10-year US Treasury yield rose above 5%, the highest in 19 years, after strong US business activity data. Fed's Collins, Musalem, and Barr supported further rate hikes. Higher US rates make the dollar more attractive, pushing EURUSD down.

    New US data and Fed comments drive dollar strength, a key counterweight to the euro.

  • German political risk and ECB's Lane downplays wage pressure Germany's far-right party won a major regional election, weakening the coalition and raising political uncertainty. ECB's Lane said no strong wage pressure, suggesting fewer hikes. These factors weigh on the euro, pushing EURUSD down.

    New political and monetary developments that could undermine euro strength.

▲1▼1

ECB hikes and signals more, but Fed's first hike in three years lifts dollar

  • Markets price more ECB hikes; banks see 2.75% or higher Money markets now price more than four additional ECB hikes, and banks like Barclays, Goldman and Rabobank expect another 25bp move in December to 2.75%. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

    Shows how far investors expect euro rates to rise, a key support for the euro.

  • Fed hikes to 3.75-4.00%, first rise in three years The Fed raised rates on September 16, six days after the ECB, and strong US retail sales and 3.4% inflation backed the move. Higher US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down to about 1.1450.

    The Fed's hike is the main new force pulling EURUSD down this period.

  • Oil and gas above ECB assumptions keep inflation high Brent above $100 and natural gas above €83/MWh exceed the ECB's worst-case assumptions, so inflation may stay high longer. This keeps the ECB tightening, which supports the euro, but high energy also hurts Europe's growth and can push investors to the dollar.

    Energy prices are the underlying force driving both ECB tightening and euro weakness.

▲3▼1

ECB hikes to 2.50% and signals more, lifting euro despite US rate pushback

  • ECB delivers first hike in two meetings, signals more The ECB raised its deposit rate to 2.50% on September 10, its second hike this year, and said inflation will stay above target through 2028. Higher euro interest rates attract global money into the euro, pushing EURUSD up. Markets now expect at least one more hike by year-end.

    The ECB's actual rate hike and further-hike signal is the main new force lifting the euro.

  • Eurozone economy resilient, ECB raises growth forecast ECB President Lagarde said she was surprised by the economy's resilience, with defense, infrastructure and AI investment supporting growth. The ECB raised its 2026 growth forecast to 0.9%. A stronger economy makes the euro more attractive and supports further rate hikes, pushing EURUSD up.

    Economic resilience gives the ECB room to keep rates high, reinforcing euro strength.

  • US rate-hike odds jump on hot PPI, capping euro US producer price inflation rose 5.4% in August, above expectations, and markets now price a 70% chance of a Fed hike on September 16, up from 61%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and limiting EURUSD's rise.

    This is the main counterweight: US rate expectations are rising too, which caps the euro's gains.

  • Oil above $100 fuels inflation, keeping ECB hawkish Brent crude surged past $105 as Middle East conflict cut energy exports, pushing eurozone inflation to 3.3%. The ECB hiked to prevent energy costs spreading. While high oil can hurt growth, it keeps the ECB tightening, which supports the euro against the dollar.

    Oil-driven inflation is the reason the ECB is hiking, directly linking energy prices to euro strength.

▲2▼1

ECB hike bets build on energy inflation; US intervention and Fed pushback cap euro

  • Eurozone inflation jumps, ECB hike bets build Eurozone inflation rose to 3.3% in August from 2.9%, driven by energy, and producer prices jumped 5.8%. Officials like Holzmann and Nagel pushed for more tightening, and markets now price a September ECB hike with near certainty. Higher expected euro interest rates pull global money into the euro, pushing EURUSD up.

    Rising euro-area inflation and hawkish ECB signals are the main new force lifting the euro.

  • Banks see ECB hiking further, rates staying higher JPMorgan and BNP Paribas now expect an extra ECB hike in December, and DBS sees the deposit rate at 2.50%, citing sticky inflation and resilient growth. Expectations of higher-for-longer euro rates attract foreign capital into the euro, supporting EURUSD.

    New forecasts of further ECB tightening extend the rate advantage that supports the euro.

  • US euro-selling intervention and Fed pushback weigh on euro European central bankers are frustrated that the US sold euros to buy yen without warning, and Bundesbank's Nagel called it a surprise. The extra euro supply weakens the euro. Meanwhile, Fed's Waller backed holding US rates, and strong August US jobs raised hike odds, both supporting the dollar and pushing EURUSD down.

    This is the main counterweight: US policy actions and data that strengthen the dollar against the euro.

  • ECB's blockchain euro plan could support long-term demand ECB's Schnabel pushed for issuing a blockchain-based euro, rejecting stablecoins, with the Pontes project launching next month. If it makes the euro more useful in digital finance, it could gradually raise demand for euros. But the effect is long-term and small for now, so it is a minor support.

    A new structural initiative that could affect future euro demand, though not an immediate price driver.

August 2026
▲2▼2

Euro Hits Two-Month High on Dollar Weakness, but Gains Capped

  • Dollar Weakness Lifts Euro Weak US jobs data and a split Fed cut September rate-hike odds, pushing the euro to a two-month high near 1.166. Treasury buybacks and Middle East de-escalation also weighed on the dollar.

    This is the main new driver of the euro's rise in August 2026.

  • Strong Eurozone Data and Hawkish ECB Support Euro Strong German trade and solid eurozone activity boosted the euro. The ECB stayed hawkish, with a September hike to 2.50% increasingly expected, making the euro more attractive.

    This is a new positive factor for the euro in August 2026.

  • US Intervention and Fed Comments Cap Euro US intervention selling euros to buy yen added euro supply and strained ECB cooperation. Fed Chair Warsh's Jackson Hole remarks and hot US PCE inflation revived US hike bets, strengthening the dollar.

    These new counterweights limited the euro's gains in August 2026.

  • Risks Tilt Against Euro Falling eurozone inflation expectations threatened ECB resolve, while stalled Iran talks and a possible US-Japan currency alliance kept risks tilted against the euro.

    These new risks prevented further euro strength in August 2026.

▼3▲1

ECB September hike bets build, but Fed pushback caps euro

  • ECB September rate hike increasingly expected The ECB is set to raise its policy rate to 2.50% in September to stop war-driven energy inflation spreading, and official Schnabel said more tightening is needed. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    A near-certain ECB hike is the main force lifting the euro this period.

  • Fed Chair Warsh hints at a US rate hike At Jackson Hole, Fed Chair Warsh said there is 'work to do' on inflation, lifting the chance of a September US hike to about 57.5% from 35%. Higher expected US rates make dollar deposits more attractive, strengthening the dollar and pushing EURUSD down.

    This is the main new counterweight that pulled the euro back from its highs.

  • Hot US inflation surprise supports the dollar A hotter-than-expected US PCE inflation reading on August 27 pushed US rates and the dollar up, sending EURUSD to about 1.1650. Stronger US inflation keeps the Fed from easing, which supports the dollar and weighs on the euro.

    It shows the US side of the rate story that is capping the euro.

  • US-Japan currency alliance keeps selling euros Citi says the US-Japan interventions reflect an informal currency alliance, with Washington selling euros to buy yen and possibly acting again if EUR/JPY nears 185-186. Extra euro supply in the market weakens the euro against the dollar.

    It is a real, ongoing drag on the euro that readers should not overlook.

▲3▼1

Euro hits two-month high as Fed hike bets fade and ECB stays hawkish

  • Fed rate-hike bets collapse, dollar loses its yield appeal US jobs data stayed weak and the Fed kept rates unchanged with a split committee, so traders cut the chance of a September hike to about 35% from 52% a week earlier. Lower expected US interest rates make dollar deposits less attractive, pushing EURUSD up.

    This is the main new force weakening the dollar and lifting the euro this period.

  • US Treasury buybacks and Middle East de-escalation weaken the dollar The US Treasury said it would more than double its bond buybacks to add market liquidity, which pushed the dollar down broadly and the euro up to about 1.166. Progress in Iran talks to reopen the Strait of Hormuz also cut safe-haven demand for the dollar.

    These are new events that directly weakened the dollar and pushed EURUSD to a two-month high.

  • Eurozone economy strengthens, keeping ECB hike on the table Eurozone business activity hit its highest since last November, with new orders growing fastest in 40 months and hiring rising for the first time this year. ECB official Lane said 3% inflation is too high. A stronger economy and likely ECB hike attract money into the euro.

    New eurozone data and ECB comments support the euro side of the pair.

  • Counterweight: consumers see lower inflation, and Middle East risk lingers Eurozone consumers' inflation expectations fell for a third month, which could soften the ECB's willingness to hike and cap the euro. Iran also threatened a fully offensive military posture after talks stalled, which could revive safe-haven dollar demand and push EURUSD down.

    This is the real counterweight that could stop the euro's rise, so readers get a fair picture.

July 2026
▲2▼2

Euro Rises on ECB Hawkishness and Weak US Data, but Gains Capped

  • ECB Hawkishness and Strong Eurozone Data Support Euro The European Central Bank kept a tough stance, with markets expecting more rate hikes as inflation stayed above target. Strong German and eurozone data, including GDP growth of 0.4% and high confidence, also lifted the euro.

    This explains a key force pushing the euro higher during the period.

  • Weak US Economic Data Weigh on Dollar Soft US inflation reports, weak GDP, and a Federal Reserve that held rates steady made the dollar less attractive. This helped push the euro to a six-week high near 1.1485.

    This highlights a major factor that weakened the dollar and supported the euro.

  • Oil Price Surge and Safe-Haven Demand Limit Euro Gains Oil prices above $100 due to Middle East tensions raised eurozone inflation but also hurt growth and increased bets on Fed rate hikes. This boosted dollar safe-haven demand, capping the euro's rise.

    This shows a counterweight that prevented larger euro gains.

  • Trade Tensions and Intervention Cap Euro Trump's tariff threats and a joint US-Japan intervention selling euros for yen added pressure. Eurozone inflation slowing to 2.8% in June also suggested the ECB might pause, limiting further euro strength.

    This points to other factors that restrained the euro's advance.

▲2▼1

ECB hike bets build as US data and yen intervention whipsaw the dollar

  • ECB signals September hike, lifting euro The ECB held its key rate at 2.25% but strongly hinted at a September hike, and markets now price the deposit rate near 2.7% by year-end and 3% by 2027. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    This is the main new force lifting the euro this period.

  • US-Japan joint intervention sells euros for yen The US and Japan jointly intervened to support the yen, selling euros to buy yen in a roughly $87 billion operation. This directly increased the supply of euros in the market, pushing the euro down against the dollar and adding geopolitical risk.

    This is a new, direct supply shock to the euro that weighs on EURUSD.

  • US data mixed: weak jobs, strong ISM and hawkish Fed Weak US jobs and soft data weakened the dollar, but strong ISM manufacturing and hawkish Fed comments later supported it. The tug-of-war between US rate-hike and rate-cut expectations keeps EURUSD volatile, with no clear direction from US data alone.

    US data is a key counterweight to the euro's rise, and its mixed nature explains the back-and-forth.

  • Eurozone GDP beats, supporting ECB hike case Eurozone second-quarter GDP rose 0.4%, beating forecasts, and business activity was strong. This supports the case for an ECB rate hike in September, making the euro more attractive to global investors and helping push EURUSD higher.

    Strong eurozone growth reinforces the ECB tightening story that lifts the euro.

▲2▼1

US jobs shock and euro-selling intervention drive euro to seven-week high

  • Weak US jobs report kills Fed rate-hike bets, lifting euro US July payrolls unexpectedly fell by 23,000, the first drop in five months, and wage growth slowed. Traders slashed the chance of a September Fed rate hike to about 44% from 58%. Lower expected US interest rates weaken the dollar, pushing EURUSD up to a seven-week high near 1.157.

    This is the main new force this period: a weak US economy makes the dollar less attractive, directly lifting the euro.

  • US sells euros to buy yen, weakening euro The US Treasury intervened to support the yen by selling euros and buying yen, without telling the ECB first. This directly increased the supply of euros in the market, pushing the euro down against the dollar. The ECB called it shocking, raising fears of strained central-bank cooperation.

    This is a new, direct action that weakens the euro and is a real counterweight to the euro's rally.

  • Strong German trade data supports euro German trade data came in better than expected, adding to signs that Europe's largest economy is holding up. A stronger eurozone economy makes the euro more attractive to global investors, helping push EURUSD higher alongside the weak US jobs news.

    It is a new eurozone-specific factor that supports the euro and helps explain the move to a seven-week high.

▲3▼1

Fed holds, US data weak, eurozone inflation up — euro hits six-week high

  • Fed holds rates, dollar falls broadly The Fed kept its key rate at 3.50–3.75% for a fifth straight meeting, with only three members wanting a hike. Because US rates are not rising, the dollar lost its appeal and fell, pushing EURUSD up to about 1.143.

    A steady Fed directly weakens the dollar, the main force lifting EURUSD this period.

  • Weak US GDP and cooling PCE knock dollar to six-week low US second-quarter GDP grew only 1.5%, below the 2.0% forecast, and core PCE inflation eased to 3.3%. Slower US growth and softer inflation mean the Fed is less likely to hike, weakening the dollar and lifting the euro to a six-week high.

    Soft US data reduce expected US rates, a key driver of dollar weakness and euro strength.

  • Eurozone GDP and confidence beat, inflation accelerates to 2.9% Eurozone second-quarter GDP rose 0.4% and economic confidence hit a five-month high, while July inflation accelerated to 2.9% on higher oil. Stronger growth and sticky inflation strengthen the case for ECB rate hikes, supporting the euro.

    Better eurozone data and higher inflation raise ECB hike odds, boosting the euro's rate appeal.

  • Trump tariff threat and oil spike weigh on euro Trump threatened steep tariffs on the EU after Brussels fined Google $1 billion, and Brent crude jumped over 6% on Iran tensions. Tariffs and costlier energy hurt the eurozone economy, a counterweight that could cap the euro's gains.

    This is the main risk pulling EURUSD down, balancing the positive drivers.

▲2▼1

Oil spike revives ECB hike bets, but dollar strength keeps euro pinned near 1.14

  • ECB signals possible September hike as oil-driven inflation risks rise The ECB held its key rate at 2.25% but President Lagarde strongly hinted at a September hike, calling inflation risks tilted to the upside. Higher expected euro interest rates attract global money into the euro, pushing EURUSD up.

    This is the main new monetary policy event of the period and directly supports the euro.

  • German 10-year bond yield hits 15-year high on ECB hike expectations Germany's 10-year yield surged to 3.21%, the highest since 2011, as markets priced two more ECB hikes by early 2027. Higher euro-area bond yields make euro deposits more attractive, lifting the euro against the dollar.

    Rising euro yields are a key channel through which ECB hike bets strengthen the euro.

  • Oil above $100 and Middle East attacks boost dollar safe-haven demand and Fed hike bets Houthi attacks on Saudi tankers sent Brent above $100, reigniting US inflation fears. Markets now price an 83% chance of a September Fed hike, up from 52% a week ago. Higher US rates and safe-haven flows strengthen the dollar, pushing EURUSD down.

    This is the main new force pulling EURUSD lower and is the counterweight to the ECB story.

  • SocGen warns oil spike may force ECB hikes but also sap eurozone growth Societe Generale says surging oil and gas could push the ECB to hike to 2.50% in September, but the same energy costs hurt eurozone growth. The bank sees a return above 1.1480 as a big ask, so the net effect on EURUSD is unclear.

    It fairly presents the real counterweight: higher energy prices can both help and hurt the euro.

▲2▼1

US inflation cools, Fed hike bets fade; euro rebounds but oil risks cap gains

  • Soft US CPI and PPI crush Fed rate-hike bets, lifting the euro US June consumer and producer inflation came in below forecasts, so traders slashed the chance of a Fed rate hike this month from 42% to 16% and for the year from 89% to 80%. Lower expected US rates weaken the dollar, pushing EURUSD up to a 3.5-week high near 1.1485.

    This is the main new force this period: softer US inflation directly reduces the dollar's rate advantage, a key driver of EURUSD.

  • Oil surge from Iran conflict cuts both ways for euro Renewed US-Iran fighting and sanctions sent oil up 9%, raising inflation fears. This could force the Fed to hike (dollar-positive) but also revives ECB hike bets (euro-positive). ING warns euro gains may stall above 1.1460 if oil keeps rising, as costlier energy hurts the eurozone economy.

    Oil is a major new factor this period, with a two-sided impact on EURUSD that explains why the euro's rally is capped.

  • ECB officials signal readiness to act, supporting euro ECB's Holzmann said no second-round inflation effects yet but the bank stands ready to act; Nagel urged caution but decisiveness if needed; Rabobank and ING note oil revives ECB hike risk. This keeps euro interest-rate appeal alive, underpinning EURUSD.

    ECB policy stance is a core driver of the euro's value versus the dollar, and this period brought fresh signals.

  • Eurozone inflation slows, ECB expected to hold rates Final June eurozone inflation was 2.8%, down from 3.2%, with core at 2.4%. Nordea expects the ECB to hold rates at its July meeting as a pause, not a pivot. Slower inflation reduces pressure to hike, limiting euro upside.

    This is a counterweight to the euro-positive ECB signals, showing why the euro isn't rising more.

▲3

ECB hawkishness and Middle East tensions drive euro higher

  • ECB signals more rate hikes, supporting euro ECB minutes showed inflation will stay above target until 2027, and markets now price nearly three rate hikes. Higher euro interest rates attract global capital, pushing EURUSD up.

    This is a key new driver: ECB's hawkish stance strengthens the euro.

  • Middle East tensions weaken dollar, lift euro US-Iran ceasefire broke down, with US strikes on Iran. The dollar usually weakens on such geopolitical risk as investors avoid US assets, helping EURUSD rise.

    New escalation in Middle East tensions is a fresh factor pushing the dollar down.

  • Strong German data boosts euro German industrial production and exports rose unexpectedly in May, signaling eurozone economic resilience. A stronger economy supports the euro, pushing EURUSD higher.

    New positive economic data from Germany supports the euro.

  • Fed rate hike bets ease, but volatility may rise Weak US jobs data and stable claims reduced Fed hike odds, weakening the dollar. However, rising FX volatility and hedging demand could cause sharp swings in EURUSD.

    This shows a counterweight: while Fed bets ease, volatility risk remains.

Q2 2026
▼3▲1

Euro Falls to One-Year Low as Fed Hawkishness and Oil Slump Weigh

  • Fed Hawkishness Draws Capital to USD Fed Chair Warsh's hawkish stance, with nine of 19 officials eyeing a year-end rate hike, pulled capital into the US dollar, pushing the euro to a one-year low near 1.1350.

    This is the main force driving the euro down against the dollar.

  • ECB Hikes Alone into Weak Growth The ECB raised rates by itself while the Eurozone economy remained weak, and President Lagarde downplayed inflation, widening the interest rate gap with the US and pressuring the euro.

    It explains why the euro struggled despite an ECB rate hike.

  • Oil Slump Cuts ECB Hike Expectations A sharp drop in oil prices from $115 to around $75 per barrel reduced the chances of further ECB rate hikes, adding to the euro's weakness.

    It shows how falling oil prices indirectly hurt the euro by lowering ECB hike odds.

  • US-Iran Peace Deal and Weak US Payrolls Lift Euro The US-Iran peace deal briefly pushed the euro above 1.1500, and later weak US payrolls (57k vs. 113k expected) sent it to a 1.5-week high, though analysts warn the dollar rally may be overdone.

    It highlights the main positive forces that temporarily lifted the euro.

June 2026
▼3▲1

Euro Falls to One-Year Low as Fed Hawkishness and Oil Slump Weigh

  • Fed Hawkishness Draws Capital to USD Fed Chair Warsh's hawkish stance, with nine of 19 officials eyeing a year-end rate hike, pulled capital into the US dollar, pushing the euro to a one-year low near 1.1350.

    This is the main force driving the euro down against the dollar.

  • ECB Hikes Alone into Weak Growth The ECB raised rates by itself while the Eurozone economy remained weak, and President Lagarde downplayed inflation, widening the interest rate gap with the US and pressuring the euro.

    It explains why the euro struggled despite an ECB rate hike.

  • Oil Slump Cuts ECB Hike Expectations A sharp drop in oil prices from $115 to around $75 per barrel reduced the chances of further ECB rate hikes, adding to the euro's weakness.

    It shows how falling oil prices indirectly hurt the euro by lowering ECB hike odds.

  • US-Iran Peace Deal and Weak US Payrolls Lift Euro The US-Iran peace deal briefly pushed the euro above 1.1500, and later weak US payrolls (57k vs. 113k expected) sent it to a 1.5-week high, though analysts warn the dollar rally may be overdone.

    It highlights the main positive forces that temporarily lifted the euro.

▲1▼1

Eurozone inflation cools, ECB hike bets fade; weak US jobs lift euro

  • Eurozone inflation cools, ECB hike bets fade Eurozone inflation slowed to 2.8% in June, below the 3% forecast, and German inflation also cooled. Traders cut bets on another ECB rate hike, reducing the euro's interest-rate appeal and pushing EURUSD down toward 1.1400.

    This is the main new force weakening the euro this period.

  • Weak US jobs data dents Fed hike expectations US June payrolls rose only 57,000, far below the 113,000 expected, and May's figure was revised down. This cooled bets on near-term Fed tightening, weakening the dollar and lifting the euro to a 1.5-week high above 1.1400.

    This is the main new force supporting the euro at the end of the period.

  • ECB still hawkish, but oil slump complicates ECB President Lagarde defended June's rate hike as necessary, and ING expects one more hike, supporting the euro. But lower oil prices reduce inflation pressure, and Commerzbank warns the ECB may not need to tighten much more, creating mixed signals.

    Shows the counterweight: ECB hawkishness supports the euro but may be fading.

▼3▲1

Euro hits one-year low as Fed hike bets and oil slump outweigh ECB

  • Fed rate-hike bets drive dollar to 13-month high, euro below 1.14 The Fed under Kevin Warsh is expected to raise rates as soon as September, pulling global money into the dollar. The euro fell below 1.1400 to a one-year low near 1.1350, as higher US rates make dollar deposits more attractive than euro ones.

    This is the main force pushing EURUSD down this period.

  • Oil price collapse cuts ECB hike odds, weakening euro support Easing US-Iran tensions and restored Hormuz oil flows sent Brent crude from $115 in May to about $75. Lower energy costs reduce inflation pressure, so traders slashed the chance of a second ECB rate hike from 50% to 20%, removing a key euro support.

    This new oil-driven shift in ECB expectations is a fresh negative for the euro.

  • ECB's Lagarde downplays inflation, signaling no aggressive tightening ECB President Lagarde said the inflation shock needs only a measured response and no forceful action, even as Eurozone PMIs stay weak with German services at a 43-month low. This contrast with the hawkish Fed widens the euro-dollar interest rate gap, pushing EURUSD down.

    Lagarde's stance is a new, direct driver of euro weakness this period.

  • Dollar rally may be overdone; lower oil and weak US data spark rebound On Friday the dollar fell for a second day as lower oil and weak US consumer sentiment cooled Fed hike expectations, lifting the euro 0.43% to 1.1418. Analysts warn the dollar-positive loop may burn out, and BofA still sees euro recovery later in 2026 on German fiscal stimulus.

    This is the real counterweight that could stop or reverse the euro's fall.

▼2▲1

Hawkish Fed under Warsh drives dollar to one-year high, euro to three-month low

  • Fed's hawkish turn under Warsh lifts USD, sinks EUR New Fed Chair Kevin Warsh's first meeting delivered a hawkish dot plot: nine of 19 officials now expect at least one rate hike by year-end. Higher US rates attract global capital to the dollar, pushing EURUSD down to a three-month low near 1.1416.

    This is the dominant new force this period, directly driving the euro to multi-month lows.

  • ECB hikes alone as other central banks hold The ECB raised rates and signaled more to come, but the BoE, SNB, Norges Bank and Riksbank stayed on hold. A lone hiker with weaker regional growth undermines the euro, as markets price downside risks for the euro area.

    Explains why ECB hikes are not supporting the euro, a key counterintuitive driver.

  • US-Iran peace deal briefly lifts euro Trump signed a memorandum with Iran to end the war, easing geopolitical tensions and weakening the safe-haven dollar. The euro rebounded above 1.1500, though the gain was short-lived as Fed rate expectations soon reasserted themselves.

    Shows a real counterweight to dollar strength, even if temporary.

  • Analysts warn dollar rally may be overdone ING cautioned the dollar's surge may not last, arguing the US-Iran deal removes a positive argument for the dollar and markets overestimate the chance of a Fed rate hike. This suggests EURUSD could stabilize or rebound if rate-hike bets fade.

    Provides a fair counterpoint that the dominant dollar-strength trend may reverse.

© 2026 MarketDXWhy